Search Result

Results for "

peripheral analgesic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Receptor (2) Adrenergic Receptor (7) Akt (3) Angiotensin Receptor (2) Cannabinoid Receptor (2) CCR (1) Cytochrome P450 (2) Dopamine Receptor (3) Drug Derivative (1) Drug Intermediate (1) ERK (4) Hydroxycarboxylic Acid Receptor (HCAR) (1) Isotope-Labeled Compounds (2) JNK (3) Lipoxygenase (1) Neuropeptide FF Receptor (1) NF-κB (1) Opioid Receptor (8) PKC (3) Potassium Channel (2) Reference Standards (5) Sodium Channel (5) Trk Receptor (4) TRP Channel (4)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Endocrinology (8) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (39)

By Targets:

5-HT Receptor (4)

Adenosine Receptor (2)

Adrenergic Receptor (7)

Akt (3)

Angiotensin Receptor (2)

Cannabinoid Receptor (2)

CCR (1)

Cytochrome P450 (2)

Dopamine Receptor (3)

Drug Derivative (1)

Drug Intermediate (1)

ERK (4)

Hydroxycarboxylic Acid Receptor (HCAR) (1)

Isotope-Labeled Compounds (2)

JNK (3)

Lipoxygenase (1)

Neuropeptide FF Receptor (1)

NF-κB (1)

Opioid Receptor (8)

PKC (3)

Potassium Channel (2)

Reference Standards (5)

Sodium Channel (5)

Trk Receptor (4)

TRP Channel (4)

By Research Areas:

Cancer (5)

Cardiovascular Disease (2)

Endocrinology (8)

Inflammation/Immunology (10)

Metabolic Disease (1)

Neurological Disease (39)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0985

Phenazopyridine hydrochloride 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-13106

Olodanrigan 4 Publications Verification EMA401; PD-126055; (S)-EMA400	Angiotensin Receptor	Cardiovascular Disease Neurological Disease Endocrinology
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-17034

Medetomidine	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine is an orally active α2-adrenoceptor agonist (K_i: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-N8487

7-Methoxyflavone	Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .

HY-P1248

Neuropeptide FF NPFF	Neuropeptide FF Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with K_i values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .

HY-16723

Funapide TV 45070; XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC₅₀ values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects .

HY-17034B

Medetomidine hydrochloride MPV785	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-171846

LY3526318	TRP Channel	Neurological Disease Inflammation/Immunology
LY3526318 is an orally active, selective TRPA1 antagonist (IC₅₀=5-6μM). LY3526318 blocks TRPA1 channels, inhibits pain signal transduction mediated by the channel, and exerts analgesic activity. LY3526318 is mainly used in the research of chronic pain-related fields, such as diabetic peripheral neuropathy, chronic low back pain, and pain caused by osteoarthritis .

HY-17391

Pamabrom	Adenosine Receptor	Endocrinology
Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K ⁺ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].

HY-122616

PF-06273340	Trk Receptor	Neurological Disease
PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC₅₀ values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .

HY-14604

Xaliproden hydrochloride 1 Publications Verification SR57746A; SR57746 hydrochloride	5-HT Receptor Dopamine Receptor Trk Receptor PKC ERK Akt JNK	Neurological Disease Metabolic Disease
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ ³⁵S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .

HY-114771

α-Truxillic acid	Drug Intermediate	Inflammation/Immunology
α-Truxillic acid is form by the dimerization of two molecules of α-trans-cinnamic acid, with anti-inflammatory activities. α-Truxillic acid has no analgesic activity, but its derivatives bound to camphor fragments exhibit significant activity in the peripheral analgesic model (writhing test) .

HY-B0985A

Phenazopyridine 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine is a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-17034BS1

Medetomidine-13C,d3 hydrochloride MPV785-¹³C,d₃	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Medetomidine-13C,d3 (hydrochloride) is a deuterated labeled Medetomidine (hydrochloride) . Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-147907

Adenosine receptor inhibitor 1	Adenosine Receptor	Neurological Disease Inflammation/Immunology Cancer
Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with K_i values of >1000, 68.5, >1000, >1000 nM for A₁AR, A_2AAR, A_2BAR, A₃AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases .

HY-16723A

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-145491

Resolvin D5	ERK NF-κB CCR	Inflammation/Immunology
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .

HY-110065

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

HY-403593

FCH-2296413	Hydroxycarboxylic Acid Receptor (HCAR)	Neurological Disease
FCH-2296413 is a potent and selective hydroxycarboxylic acid receptor (HCAR) agonist with an EC₅₀ of 4.4-8.6 nM. FCH-2296413 exhibits analgesic activity and can be used for the research of peripheral pain-related diseases .

HY-13106A

Olodanrigan sodium EMA401 sodium; PD-126055 sodium	Angiotensin Receptor	Neurological Disease Endocrinology
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-P5907

Helianorphin-19	Opioid Receptor	Neurological Disease
Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a K_i of 21 nM and an EC₅₀ of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain .

HY-17034BR

Medetomidine hydrochloride (Standard) MPV785 (Standard)	Adrenergic Receptor Reference Standards	Neurological Disease Endocrinology
Medetomidine (hydrochloride) (Standard) is the analytical standard of Medetomidine (hydrochloride). This product is intended for research and analytical applications. Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-174845

Nav1.8-IN-20	Sodium Channel	Neurological Disease
Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC₅₀ value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-N9854

Icariside E4	Potassium Channel	Inflammation/Immunology
Icariside E4 is an antinociceptive agent, and can be isolated from Tabebuia roseo-alba. Icariside E4 has peripheral analgesic activity by ATP-sensitive K ⁺ channel-dependent mechanisms. Icariside E4 also has anti-oxidant, anti-Alzheimer and anti-inflammatory effects .

HY-113826

L-656224	Lipoxygenase	Others
L-656224 is an orally active, potent and selective inhibitor of leukotriene biosynthesis in intact rat and human leukocytes and CXBG mastocytoma cells (IC₅₀ values, 18-240 nM) and of human leukocyte and porcine leukocyte 5-lipoxygenase (IC₅₀, 4 x 10 ^-7 M). L-656224 is promising for research of asthma and peripheral analgesic agents .

HY-129668

Bremazocine	Adrenergic Receptor	Neurological Disease
Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .

HY-106147

Frakefamide	Opioid Receptor	Neurological Disease
Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-106147B

Frakefamide TFA	Opioid Receptor	Neurological Disease
Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-129787

PF-03550096	Cannabinoid Receptor	Neurological Disease
PF-03550096 is an orally active synthetic cannabinoid (CB) that selectively targets peripheral CB2 receptors with a K_i value of 7.9 nM. PF-03550096 has analgesic activity .

HY-N7514

Strictosidinic acid	5-HT Receptor	Neurological Disease
Strictosidinic acid, an orally active glycoside indole monoterpene alkaloid isolated from Psychotria myriantha leaves, inhibits precursor enzymes of 5-HT biosynthesis and reduces the 5-HT levels. Strictosidinic acid has peripheral analgesic and antipyretic activities in mice .

HY-P1253

α-Endorphin (human)	Opioid Receptor	Neurological Disease
α-Endorphin (human) is a neuropeptide, that acts on the central nervous system (CNS) and peripheral nervous system (PNS). α-Endorphin (human) binds μ-opioid receptor, and exhibits analgesic efficacy. α-Endorphin (human) regulates sexual behaviors and pleasure felling .

HY-P10203

μ/κ/δ opioid receptor agonist 1	Opioid Receptor	Inflammation/Immunology
μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .

HY-17034R

Medetomidine (Standard)	Adrenergic Receptor Reference Standards	Neurological Disease Endocrinology
Medetomidine (Standard) is the analytical standard of Medetomidine. This product is intended for research and analytical applications. Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-159924

DBPR116	Opioid Receptor	Neurological Disease
DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic .

HY-W717221

Medetomidine-d5 (d5-Major)	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Medetomidine-d₅ (d5-Major) is the deuterium labeled Medetomidine (HY-17034). Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-B0985R

Phenazopyridine hydrochloride (Standard)	Reference Standards TRP Channel	Neurological Disease
Phenazopyridine (hydrochloride) (Standard) is the analytical standard of Phenazopyridine (hydrochloride). This product is intended for research and analytical applications. Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-111011

CR 665 acetate JNJ 38488502 acetate; FE 200665 acetate	Opioid Receptor	Neurological Disease
CR 665 (JNJ 38488502) acetate is a kappa-opioid agonist that may effectively treat visceral pain by activating receptors on afferent nerves within the gut. CR 665 acetate exhibits peripheral selectivity, differentiating its pharmacokinetic profile from that of non-selective opioids like oxycodone. CR 665 acetate has demonstrated a beneficial effect on visceral pain tolerance thresholds without the delayed analgesic response characteristic of opioids that penetrate the brain. CR 665 acetate is proposed for use in managing postoperative pain due to its pain-relieving properties.

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-119820

Xaliproden free base SR57746A free base	Akt Dopamine Receptor Trk Receptor 5-HT Receptor PKC JNK ERK	Neurological Disease
Xaliproden (SR57746) free base is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden free base activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden free base also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ ³⁵S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden free base exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden free base also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden free base can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .

HY-169844

D-19050	Drug Derivative	Neurological Disease
D-19050 is a derivative of triaminopyridine and is an analgesic with both central and peripheral effects .

HY-P992012

CA1001	Opioid Receptor	Neurological Disease Cancer
CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual opioid receptor agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.

HY-N18124

1-O-Tigloyl-1-O-debenzoylohchinal	Others	Neurological Disease
1-O-Tigloyl-1-O-debenzoylohchinal is an orally active limonoid-type triterpenoid anti-inflammatory and peripheral analgesic agent isolated from the fruits of Melia toosendan. 1-O-Tigloyl-1-O-debenzoylohchinal significantly inhibits acetic acid (HY-Y0319)-induced increase in vascular permeability, λ-Carrageenan (HY-N9470)-induced paw edema, and acetic acid-induced writhing response in mice. 1-O-Tigloyl-1-O-debenzoylohchinal shows no significant analgesic effect in the hot-plate test, and acts mainly on the peripheral rather than the central nervous system. 1-O-Tigloyl-1-O-debenzoylohchinal can be widely used in the research of acute or chronic inflammation, stomachache and other related diseases .

HY-N8487R

7-Methoxyflavone (Standard)	Reference Standards Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
7-Methoxyflavone (Standard) is the analytical standard of 7-Methoxyflavone (HY-N8487). This product is intended for research and analytical applications. 7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .

HY-14604R

Xaliproden hydrochloride (Standard) SR57746A (Standard); SR57746 hydrochloride (Standard)	Reference Standards Akt Dopamine Receptor Trk Receptor 5-HT Receptor PKC JNK ERK	Neurological Disease Cancer
Xaliproden (hydrochloride) (Standard) is the analytical standard of Xaliproden (hydrochloride). This product is intended for research and analytical applications. Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ ³⁵S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .

Cat. No.	Product Name	Target	Research Area